| pubmed-article:19476408 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0001554 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0005767 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0449438 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0004063 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0311404 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C2745888 | lld:lifeskim |
| pubmed-article:19476408 | lifeskim:mentions | umls-concept:C0205210 | lld:lifeskim |
| pubmed-article:19476408 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:19476408 | pubmed:dateCreated | 2009-7-27 | lld:pubmed |
| pubmed-article:19476408 | pubmed:abstractText | We used doxorubicin-based chemotherapy as a clinical model for oxidative assault. Study recruited 23 breast cancer patients and collected blood samples before (T0), at 1 (T1) and 24 hours (T24) after treatment administration. Measurements included protein carbonyl content (PPCC), malondialdehyde (MDA), and alpha- and gamma-tocopherols in plasma and total glutathione content in erythrocytes (erGSHt). In all subjects, PPCC and MDA levels did not change. erGSHt levels increased at T24 by 8% (p=0.03). Levels of alpha, gamma, and total tocopherols progressively decreased by 7%-15% (p <0.05). In subjects with low erGSHt levels (below median), PPCC mean levels progressively increased from 0.35 (T0) to 0.56 (T1) and 0.72 nmol carbonyl/mg protein (T24) (p =0.2). These results indicate that (1) plasma MDA is not a sensitive biomarker in humans; (2) PPCC potentially may be used, if antioxidant reserves are taken into account; (3) antioxidant reserves play an important role in the reaction to oxidative stress. | lld:pubmed |
| pubmed-article:19476408 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19476408 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19476408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19476408 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19476408 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:19476408 | pubmed:issn | 1366-5804 | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:WangFrancesF | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:MarcomP... | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:CraftNealN | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:Il'yasovaDora... | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:MarksJeffreyJ | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:ArredondoFran... | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:MixonGabrielG | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:SpasojevichIv... | lld:pubmed |
| pubmed-article:19476408 | pubmed:author | pubmed-author:DiGiulioRicha... | lld:pubmed |
| pubmed-article:19476408 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19476408 | pubmed:volume | 14 | lld:pubmed |
| pubmed-article:19476408 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19476408 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19476408 | pubmed:pagination | 321-5 | lld:pubmed |
| pubmed-article:19476408 | pubmed:dateRevised | 2010-9-27 | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:meshHeading | pubmed-meshheading:19476408... | lld:pubmed |
| pubmed-article:19476408 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19476408 | pubmed:articleTitle | Markers of oxidative status in a clinical model of oxidative assault: a pilot study in human blood following doxorubicin administration. | lld:pubmed |
| pubmed-article:19476408 | pubmed:affiliation | Duke Comprehensive Cancer Center, Durham, NC 27710, USA. dora.ilyasova@duke.edu | lld:pubmed |
| pubmed-article:19476408 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:19476408 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:19476408 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
